-
1
-
-
85013312416
-
Tumor angiogenesis: therapeutic implications
-
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
-
(1971)
N Engl J Med
, vol.285
, pp. 1182-1186
-
-
Folkman, J.1
-
2
-
-
0030447757
-
Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels
-
Larcher F., Robles A.I., Duran H., Murillas R., Quintanilla M., Cano A., et al. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res 56 (1996) 5391-5396
-
(1996)
Cancer Res
, vol.56
, pp. 5391-5396
-
-
Larcher, F.1
Robles, A.I.2
Duran, H.3
Murillas, R.4
Quintanilla, M.5
Cano, A.6
-
3
-
-
0036054742
-
Vascular endothelial growth factor: regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy
-
Conti C.J. Vascular endothelial growth factor: regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy. Oncologist 7 suppl 3 (2002) 4-11
-
(2002)
Oncologist
, vol.7
, Issue.SUPPL. 3
, pp. 4-11
-
-
Conti, C.J.1
-
4
-
-
0032770860
-
Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas
-
Streit M., Velasco P., Brown L.F., Skobe M., Richard L., Riccardi L., et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 155 (1999) 441-452
-
(1999)
Am J Pathol
, vol.155
, pp. 441-452
-
-
Streit, M.1
Velasco, P.2
Brown, L.F.3
Skobe, M.4
Richard, L.5
Riccardi, L.6
-
5
-
-
0026006134
-
Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma
-
Castle V., Varani J., Fligiel S., Prochownik E.V., and Dixit V. Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma. J Clin Invest 87 (1991) 1883-1888
-
(1991)
J Clin Invest
, vol.87
, pp. 1883-1888
-
-
Castle, V.1
Varani, J.2
Fligiel, S.3
Prochownik, E.V.4
Dixit, V.5
-
6
-
-
0034980383
-
Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin
-
Shimizu T., Izumi H., Oga A., Furumoto H., Murakami T., Ofuji R., et al. Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin. Dermatology 202 (2001) 203-206
-
(2001)
Dermatology
, vol.202
, pp. 203-206
-
-
Shimizu, T.1
Izumi, H.2
Oga, A.3
Furumoto, H.4
Murakami, T.5
Ofuji, R.6
-
7
-
-
17444410011
-
Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin
-
Maubec E., Duvillard P., Velasco V., Crickx B., and Avril M.F. Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. Anticancer Res 25 (2005) 1205-1210
-
(2005)
Anticancer Res
, vol.25
, pp. 1205-1210
-
-
Maubec, E.1
Duvillard, P.2
Velasco, V.3
Crickx, B.4
Avril, M.F.5
-
8
-
-
34250879547
-
Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab
-
Suen J.K., Bressler L., Shord S.S., Warso M., and Villano J.L. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs 18 (2007) 827-829
-
(2007)
Anticancer Drugs
, vol.18
, pp. 827-829
-
-
Suen, J.K.1
Bressler, L.2
Shord, S.S.3
Warso, M.4
Villano, J.L.5
-
9
-
-
34447517671
-
Treatment of recurrent squamous cell carcinoma of the skin with cetuximab
-
Bauman J.E., Eaton K.D., and Martins R.G. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol 143 (2007) 889-892
-
(2007)
Arch Dermatol
, vol.143
, pp. 889-892
-
-
Bauman, J.E.1
Eaton, K.D.2
Martins, R.G.3
-
10
-
-
46049104966
-
Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study
-
Thariat J., Ahamad A., El-Naggar A.K., Williams M.D., Holsinger F.C., Glisson B.S., et al. Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study. Cancer 112 (2008) 2698-2709
-
(2008)
Cancer
, vol.112
, pp. 2698-2709
-
-
Thariat, J.1
Ahamad, A.2
El-Naggar, A.K.3
Williams, M.D.4
Holsinger, F.C.5
Glisson, B.S.6
-
11
-
-
33750380921
-
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma
-
Ramadan K.M., McKenna K.E., and Morris T.C. Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma. Lancet Oncol 7 (2006) 958-959
-
(2006)
Lancet Oncol
, vol.7
, pp. 958-959
-
-
Ramadan, K.M.1
McKenna, K.E.2
Morris, T.C.3
-
12
-
-
28244462756
-
Microvessel density and HIF-1alpha expression correlate with malignant potential in fibrohistiocytic tumors
-
Koga K., Nabeshima K., Nishimura N., Shishime M., Nakayama J., and Iwasaki H. Microvessel density and HIF-1alpha expression correlate with malignant potential in fibrohistiocytic tumors. Eur J Dermatol 15 (2005) 465-469
-
(2005)
Eur J Dermatol
, vol.15
, pp. 465-469
-
-
Koga, K.1
Nabeshima, K.2
Nishimura, N.3
Shishime, M.4
Nakayama, J.5
Iwasaki, H.6
-
13
-
-
0034659658
-
Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo
-
Westphal J.R., Van't Hullenaar R., Peek R., Willems R.W., Crickard K., Crickard U., et al. Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Int J Cancer 86 (2000) 768-776
-
(2000)
Int J Cancer
, vol.86
, pp. 768-776
-
-
Westphal, J.R.1
Van't Hullenaar, R.2
Peek, R.3
Willems, R.W.4
Crickard, K.5
Crickard, U.6
-
14
-
-
0034283023
-
Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts
-
Rofstad E.K., and Halsor E.F. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res 60 (2000) 4932-4938
-
(2000)
Cancer Res
, vol.60
, pp. 4932-4938
-
-
Rofstad, E.K.1
Halsor, E.F.2
-
15
-
-
0042674080
-
Limitations of the immunocytochemical detection of isolated tumor cells in frozen samples of bone marrow obtained from melanoma patients
-
Schadendorf D., Dorn-Beineke A., Borelli S., Riethmuller G., and Pantel K. Limitations of the immunocytochemical detection of isolated tumor cells in frozen samples of bone marrow obtained from melanoma patients. Exp Dermatol 12 (2003) 165-171
-
(2003)
Exp Dermatol
, vol.12
, pp. 165-171
-
-
Schadendorf, D.1
Dorn-Beineke, A.2
Borelli, S.3
Riethmuller, G.4
Pantel, K.5
-
16
-
-
0032960519
-
Role of interleukin-8 in tumor growth and metastasis of human melanoma
-
Bar-Eli M. Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 67 (1999) 12-18
-
(1999)
Pathobiology
, vol.67
, pp. 12-18
-
-
Bar-Eli, M.1
-
17
-
-
9744253054
-
Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3 K signaling
-
Graells J., Vinyals A., Figueras A., Llorens A., Moreno A., Marcoval J., et al. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3 K signaling. J Invest Dermatol 123 (2004) 1151-1161
-
(2004)
J Invest Dermatol
, vol.123
, pp. 1151-1161
-
-
Graells, J.1
Vinyals, A.2
Figueras, A.3
Llorens, A.4
Moreno, A.5
Marcoval, J.6
-
18
-
-
1942442169
-
Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice
-
Bedogni B., O'Neill M.S., Welford S.M., Bouley D.M., Giaccia A.J., Denko N.C., et al. Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res 64 (2004) 2552-2560
-
(2004)
Cancer Res
, vol.64
, pp. 2552-2560
-
-
Bedogni, B.1
O'Neill, M.S.2
Welford, S.M.3
Bouley, D.M.4
Giaccia, A.J.5
Denko, N.C.6
-
19
-
-
33847417986
-
Overexpression of Akt converts radial growth melanoma to vertical growth melanoma
-
Govindarajan B., Sligh J.E., Vincent B.J., Li M., Canter J.A., Nickoloff B.J., et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 117 (2007) 719-729
-
(2007)
J Clin Invest
, vol.117
, pp. 719-729
-
-
Govindarajan, B.1
Sligh, J.E.2
Vincent, B.J.3
Li, M.4
Canter, J.A.5
Nickoloff, B.J.6
-
20
-
-
34447299171
-
Expression of activated Akt in benign nevi, Spitz nevi and melanomas
-
Kantrow S.M., Boyd A.S., Ellis D.L., Nanney L.B., Richmond A., Shyr Y., et al. Expression of activated Akt in benign nevi, Spitz nevi and melanomas. J Cutan Pathol 34 (2007) 593-596
-
(2007)
J Cutan Pathol
, vol.34
, pp. 593-596
-
-
Kantrow, S.M.1
Boyd, A.S.2
Ellis, D.L.3
Nanney, L.B.4
Richmond, A.5
Shyr, Y.6
-
21
-
-
33749472634
-
Role of p53 up-regulated modulator of apoptosis and phosphorylated Akt in melanoma cell growth, apoptosis, and patient survival
-
Karst A.M., Dai D.L., Cheng J.Q., and Li G. Role of p53 up-regulated modulator of apoptosis and phosphorylated Akt in melanoma cell growth, apoptosis, and patient survival. Cancer Res 66 (2006) 9221-9226
-
(2006)
Cancer Res
, vol.66
, pp. 9221-9226
-
-
Karst, A.M.1
Dai, D.L.2
Cheng, J.Q.3
Li, G.4
-
22
-
-
40649126759
-
mTOR is activated in the majority of malignant melanomas
-
Karbowniczek M., Spittle C.S., Morrison T., Wu H., and Henske E.P. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 128 (2008) 980-987
-
(2008)
J Invest Dermatol
, vol.128
, pp. 980-987
-
-
Karbowniczek, M.1
Spittle, C.S.2
Morrison, T.3
Wu, H.4
Henske, E.P.5
-
23
-
-
33947355893
-
Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression
-
Kurschat P., Eming S., Nashan D., Krieg T., and Mauch C. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression. Br J Dermatol 156 (2007) 653-658
-
(2007)
Br J Dermatol
, vol.156
, pp. 653-658
-
-
Kurschat, P.1
Eming, S.2
Nashan, D.3
Krieg, T.4
Mauch, C.5
-
24
-
-
12944254447
-
Therapy of hematogenous melanoma brain metastases with endostatin
-
Kirsch M., Weigel P., Pinzer T., Carroll R.S., Black P.M., Schackert H.K., et al. Therapy of hematogenous melanoma brain metastases with endostatin. Clin Cancer Res 11 (2005) 1259-1267
-
(2005)
Clin Cancer Res
, vol.11
, pp. 1259-1267
-
-
Kirsch, M.1
Weigel, P.2
Pinzer, T.3
Carroll, R.S.4
Black, P.M.5
Schackert, H.K.6
-
25
-
-
1642535552
-
Inhibition of cytokine-induced microvascular arrest of tumor cells by recombinant endostatin prevents experimental hepatic melanoma metastasis
-
Mendoza L., Valcarcel M., Carrascal T., Egilegor E., Salado C., Sim B.K., et al. Inhibition of cytokine-induced microvascular arrest of tumor cells by recombinant endostatin prevents experimental hepatic melanoma metastasis. Cancer Res 64 (2004) 304-310
-
(2004)
Cancer Res
, vol.64
, pp. 304-310
-
-
Mendoza, L.1
Valcarcel, M.2
Carrascal, T.3
Egilegor, E.4
Salado, C.5
Sim, B.K.6
-
26
-
-
0031454617
-
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
-
O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
-
(1997)
Cell
, vol.88
, pp. 277-285
-
-
O'Reilly, M.S.1
Boehm, T.2
Shing, Y.3
Fukai, N.4
Vasios, G.5
Lane, W.S.6
-
27
-
-
0002158323
-
Zinc ligand-disrupted recombinant human endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile
-
Sim B.K., Fogler W.E., Zhou X.H., Liang H., Madsen J.W., Luu K., et al. Zinc ligand-disrupted recombinant human endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis 3 (1999) 41-51
-
(1999)
Angiogenesis
, vol.3
, pp. 41-51
-
-
Sim, B.K.1
Fogler, W.E.2
Zhou, X.H.3
Liang, H.4
Madsen, J.W.5
Luu, K.6
-
28
-
-
42149105036
-
Combined effects of radiotherapy and endostatin gene therapy in melanoma tumor model
-
Wu D.S., Wu C.M., Huang T.H., and Xie Q.D. Combined effects of radiotherapy and endostatin gene therapy in melanoma tumor model. Radiat Environ Biophys 47 (2008) 285-291
-
(2008)
Radiat Environ Biophys
, vol.47
, pp. 285-291
-
-
Wu, D.S.1
Wu, C.M.2
Huang, T.H.3
Xie, Q.D.4
-
29
-
-
34249011849
-
Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents
-
Moschos S.J., Odoux C., Land S.R., Agarwala S., Friedland D., Volker K.M., et al. Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res 17 (2007) 193-200
-
(2007)
Melanoma Res
, vol.17
, pp. 193-200
-
-
Moschos, S.J.1
Odoux, C.2
Land, S.R.3
Agarwala, S.4
Friedland, D.5
Volker, K.M.6
-
30
-
-
46249106819
-
Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma
-
Gonzalez-Cao M., Viteri S., Diaz-Lagares A., Gonzalez A., Redondo P., Nieto Y., et al. Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma. Oncology 74 (2008) 12-16
-
(2008)
Oncology
, vol.74
, pp. 12-16
-
-
Gonzalez-Cao, M.1
Viteri, S.2
Diaz-Lagares, A.3
Gonzalez, A.4
Redondo, P.5
Nieto, Y.6
-
31
-
-
34547451603
-
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma
-
Varker K.A., Biber J.E., Kefauver C., Jensen R., Lehman A., Young D., et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 14 (2007) 2367-2376
-
(2007)
Ann Surg Oncol
, vol.14
, pp. 2367-2376
-
-
Varker, K.A.1
Biber, J.E.2
Kefauver, C.3
Jensen, R.4
Lehman, A.5
Young, D.6
-
32
-
-
36849048282
-
Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma
-
Terheyden P., Hofmann M.A., Weininger M., Brocker E.B., and Becker J.C. Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma. J Cancer Res Clin Oncol 133 (2007) 897-901
-
(2007)
J Cancer Res Clin Oncol
, vol.133
, pp. 897-901
-
-
Terheyden, P.1
Hofmann, M.A.2
Weininger, M.3
Brocker, E.B.4
Becker, J.C.5
-
33
-
-
33748325763
-
Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis
-
Eisen T., Ahmad T., Flaherty K.T., Gore M., Kaye S., Marais R., et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 95 (2006) 581-586
-
(2006)
Br J Cancer
, vol.95
, pp. 581-586
-
-
Eisen, T.1
Ahmad, T.2
Flaherty, K.T.3
Gore, M.4
Kaye, S.5
Marais, R.6
-
34
-
-
51049095131
-
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel
-
Flaherty K.T., Schiller J., Schuchter L.M., Liu G., Tuveson D.A., Redlinger M., et al. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 14 (2008) 4836-4842
-
(2008)
Clin Cancer Res
, vol.14
, pp. 4836-4842
-
-
Flaherty, K.T.1
Schiller, J.2
Schuchter, L.M.3
Liu, G.4
Tuveson, D.A.5
Redlinger, M.6
-
35
-
-
43749110700
-
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group
-
McDermott D.F., Sosman J.A., Gonzalez R., Hodi F.S., Linette G.P., Richards J., et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 26 (2008) 2178-2185
-
(2008)
J Clin Oncol
, vol.26
, pp. 2178-2185
-
-
McDermott, D.F.1
Sosman, J.A.2
Gonzalez, R.3
Hodi, F.S.4
Linette, G.P.5
Richards, J.6
-
36
-
-
49249137986
-
Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2
-
Molhoek K.R., Griesemann H., Shu J., Gershenwald J.E., Brautigan D.L., and Slingluff Jr. C.L. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res 68 (2008) 4392-4397
-
(2008)
Cancer Res
, vol.68
, pp. 4392-4397
-
-
Molhoek, K.R.1
Griesemann, H.2
Shu, J.3
Gershenwald, J.E.4
Brautigan, D.L.5
Slingluff Jr., C.L.6
-
37
-
-
38749126155
-
Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines
-
Bundscherer A., Hafner C., Maisch T., Becker B., Landthaler M., and Vogt T. Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. Oncol Rep 19 (2008) 547-553
-
(2008)
Oncol Rep
, vol.19
, pp. 547-553
-
-
Bundscherer, A.1
Hafner, C.2
Maisch, T.3
Becker, B.4
Landthaler, M.5
Vogt, T.6
-
38
-
-
47349099502
-
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells
-
Lasithiotakis K.G., Sinnberg T.W., Schittek B., Flaherty K.T., Kulms D., Maczey E., et al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol 128 (2008) 2013-2023
-
(2008)
J Invest Dermatol
, vol.128
, pp. 2013-2023
-
-
Lasithiotakis, K.G.1
Sinnberg, T.W.2
Schittek, B.3
Flaherty, K.T.4
Kulms, D.5
Maczey, E.6
-
39
-
-
34249799034
-
CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model
-
Thallinger C., Poeppl W., Pratscher B., Mayerhofer M., Valent P., Tappeiner G., et al. CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model. Pharmacology 79 (2007) 207-213
-
(2007)
Pharmacology
, vol.79
, pp. 207-213
-
-
Thallinger, C.1
Poeppl, W.2
Pratscher, B.3
Mayerhofer, M.4
Valent, P.5
Tappeiner, G.6
-
40
-
-
0028129059
-
Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor
-
Chirivi R.G., Garofalo A., Crimmin M.J., Bawden L.J., Stoppacciaro A., Brown P.D., et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58 (1994) 460-464
-
(1994)
Int J Cancer
, vol.58
, pp. 460-464
-
-
Chirivi, R.G.1
Garofalo, A.2
Crimmin, M.J.3
Bawden, L.J.4
Stoppacciaro, A.5
Brown, P.D.6
-
41
-
-
0036830078
-
Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group
-
Quirt I., Bodurth A., Lohmann R., Rusthoven J., Belanger K., Young V., et al. Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 20 (2002) 431-437
-
(2002)
Invest New Drugs
, vol.20
, pp. 431-437
-
-
Quirt, I.1
Bodurth, A.2
Lohmann, R.3
Rusthoven, J.4
Belanger, K.5
Young, V.6
-
42
-
-
39049092700
-
Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines
-
Sorolla A., Yeramian A., Dolcet X., Perez de Santos A.M., Llobet D., Schoenenberger J.A., et al. Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines. Br J Dermatol 158 (2008) 496-504
-
(2008)
Br J Dermatol
, vol.158
, pp. 496-504
-
-
Sorolla, A.1
Yeramian, A.2
Dolcet, X.3
Perez de Santos, A.M.4
Llobet, D.5
Schoenenberger, J.A.6
-
43
-
-
20444364475
-
A phase II study of bortezomib in the treatment of metastatic malignant melanoma
-
Markovic S.N., Geyer S.M., Dawkins F., Sharfman W., Albertini M., Maples W., et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103 (2005) 2584-2589
-
(2005)
Cancer
, vol.103
, pp. 2584-2589
-
-
Markovic, S.N.1
Geyer, S.M.2
Dawkins, F.3
Sharfman, W.4
Albertini, M.5
Maples, W.6
-
44
-
-
34249990658
-
A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma
-
Markovic S.N., Suman V.J., Rao R.A., Ingle J.N., Kaur J.S., Erickson L.A., et al. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 30 (2007) 303-309
-
(2007)
Am J Clin Oncol
, vol.30
, pp. 303-309
-
-
Markovic, S.N.1
Suman, V.J.2
Rao, R.A.3
Ingle, J.N.4
Kaur, J.S.5
Erickson, L.A.6
-
45
-
-
38849123472
-
Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma
-
Chumsri S., Zhao M., Garofalo M., Burger A., Hamburger A., Zhao F., et al. Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma. Leuk Lymphoma 49 (2008) 359-361
-
(2008)
Leuk Lymphoma
, vol.49
, pp. 359-361
-
-
Chumsri, S.1
Zhao, M.2
Garofalo, M.3
Burger, A.4
Hamburger, A.5
Zhao, F.6
-
46
-
-
0029834676
-
Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sézary syndrome
-
Zhang Q., Nowak I., Vonderheid E.C., Rook A.H., Kadin M.E., Nowell P.C., et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sézary syndrome. Proc Natl Acad Sci U S A 93 (1996) 9148-9153
-
(1996)
Proc Natl Acad Sci U S A
, vol.93
, pp. 9148-9153
-
-
Zhang, Q.1
Nowak, I.2
Vonderheid, E.C.3
Rook, A.H.4
Kadin, M.E.5
Nowell, P.C.6
-
47
-
-
34948833649
-
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma
-
Zinzani P.L., Musuraca G., Tani M., Stefoni V., Marchi E., Fina M., et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (2007) 4293-4297
-
(2007)
J Clin Oncol
, vol.25
, pp. 4293-4297
-
-
Zinzani, P.L.1
Musuraca, G.2
Tani, M.3
Stefoni, V.4
Marchi, E.5
Fina, M.6
-
48
-
-
0035866812
-
The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B
-
Montaner S., Sodhi A., Pece S., Mesri E.A., and Gutkind J.S. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B. Cancer Res 61 (2001) 2641-2648
-
(2001)
Cancer Res
, vol.61
, pp. 2641-2648
-
-
Montaner, S.1
Sodhi, A.2
Pece, S.3
Mesri, E.A.4
Gutkind, J.S.5
-
49
-
-
0034282553
-
The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha
-
Sodhi A., Montaner S., Patel V., Zohar M., Bais C., Mesri E.A., et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 60 (2000) 4873-4880
-
(2000)
Cancer Res
, vol.60
, pp. 4873-4880
-
-
Sodhi, A.1
Montaner, S.2
Patel, V.3
Zohar, M.4
Bais, C.5
Mesri, E.A.6
-
50
-
-
0037772150
-
Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes
-
Montaner S., Sodhi A., Molinolo A., Bugge T.H., Sawai E.T., He Y., et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 3 (2003) 23-36
-
(2003)
Cancer Cell
, vol.3
, pp. 23-36
-
-
Montaner, S.1
Sodhi, A.2
Molinolo, A.3
Bugge, T.H.4
Sawai, E.T.5
He, Y.6
-
51
-
-
0029993747
-
Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma
-
Brown L.F., Tognazzi K., Dvorak H.F., and Harrist T.J. Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 148 (1996) 1065-1074
-
(1996)
Am J Pathol
, vol.148
, pp. 1065-1074
-
-
Brown, L.F.1
Tognazzi, K.2
Dvorak, H.F.3
Harrist, T.J.4
-
52
-
-
0029847089
-
Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma
-
Cornali E., Zietz C., Benelli R., Weninger W., Masiello L., Breier G., et al. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am J Pathol 149 (1996) 1851-1869
-
(1996)
Am J Pathol
, vol.149
, pp. 1851-1869
-
-
Cornali, E.1
Zietz, C.2
Benelli, R.3
Weninger, W.4
Masiello, L.5
Breier, G.6
-
53
-
-
33644783914
-
Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model
-
Ferrario A., and Gomer C.J. Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model. J Environ Pathol Toxicol Oncol 25 (2006) 251-259
-
(2006)
J Environ Pathol Toxicol Oncol
, vol.25
, pp. 251-259
-
-
Ferrario, A.1
Gomer, C.J.2
-
54
-
-
29544438046
-
Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma
-
Gutierrez-Dalmau A., Sanchez-Fructuoso A., Sanz-Guajardo A., Mazuecos A., Franco A., Rial M.C., et al. Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma. Transplant Proc 37 (2005) 3836-3838
-
(2005)
Transplant Proc
, vol.37
, pp. 3836-3838
-
-
Gutierrez-Dalmau, A.1
Sanchez-Fructuoso, A.2
Sanz-Guajardo, A.3
Mazuecos, A.4
Franco, A.5
Rial, M.C.6
-
55
-
-
33645458234
-
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation
-
Campistol J.M., Eris J., Oberbauer R., Friend P., Hutchison B., Morales J.M., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17 (2006) 581-589
-
(2006)
J Am Soc Nephrol
, vol.17
, pp. 581-589
-
-
Campistol, J.M.1
Eris, J.2
Oberbauer, R.3
Friend, P.4
Hutchison, B.5
Morales, J.M.6
-
56
-
-
20144367584
-
Sirolimus for Kaposi's sarcoma in renal-transplant recipients
-
Stallone G., Schena A., Infante B., Di Paolo S., Loverre A., Maggio G., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352 (2005) 1317-1323
-
(2005)
N Engl J Med
, vol.352
, pp. 1317-1323
-
-
Stallone, G.1
Schena, A.2
Infante, B.3
Di Paolo, S.4
Loverre, A.5
Maggio, G.6
-
57
-
-
44249117090
-
Kaposi's sarcoma resolves after sirolimus therapy in a patient with pemphigus vulgaris
-
Saggar S., Zeichner J.A., Brown T.T., Phelps R.G., and Cohen S.R. Kaposi's sarcoma resolves after sirolimus therapy in a patient with pemphigus vulgaris. Arch Dermatol 144 (2008) 654-657
-
(2008)
Arch Dermatol
, vol.144
, pp. 654-657
-
-
Saggar, S.1
Zeichner, J.A.2
Brown, T.T.3
Phelps, R.G.4
Cohen, S.R.5
-
58
-
-
44249102076
-
Classic Mediterranean Kaposi's sarcoma regression with sirolimus treatment
-
Guenova E., Metzler G., Hoetzenecker W., Berneburg M., and Rocken M. Classic Mediterranean Kaposi's sarcoma regression with sirolimus treatment. Arch Dermatol 144 (2008) 692-693
-
(2008)
Arch Dermatol
, vol.144
, pp. 692-693
-
-
Guenova, E.1
Metzler, G.2
Hoetzenecker, W.3
Berneburg, M.4
Rocken, M.5
-
59
-
-
0034872059
-
Management of Kaposi sarcoma: the role of interferon and thalidomide
-
Krown S.E. Management of Kaposi sarcoma: the role of interferon and thalidomide. Curr Opin Oncol 13 (2001) 374-381
-
(2001)
Curr Opin Oncol
, vol.13
, pp. 374-381
-
-
Krown, S.E.1
-
60
-
-
40649102193
-
Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: a phase I to II, open-label trial in 17 patients
-
Celestin Schartz N.E., Chevret S., Paz C., Kerob D., Verola O., Morel P., et al. Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: a phase I to II, open-label trial in 17 patients. J Am Acad Dermatol 58 (2008) 585-591
-
(2008)
J Am Acad Dermatol
, vol.58
, pp. 585-591
-
-
Celestin Schartz, N.E.1
Chevret, S.2
Paz, C.3
Kerob, D.4
Verola, O.5
Morel, P.6
-
61
-
-
34548477395
-
Thalidomide in the treatment of Kaposi's sarcoma
-
Rubegni P., Sbano P., De Aloe G., Flori M.L., and Fimiani M. Thalidomide in the treatment of Kaposi's sarcoma. Dermatology 215 (2007) 240-244
-
(2007)
Dermatology
, vol.215
, pp. 240-244
-
-
Rubegni, P.1
Sbano, P.2
De Aloe, G.3
Flori, M.L.4
Fimiani, M.5
-
62
-
-
39149092712
-
Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies
-
Koontz B.F., Miles E.F., Rubio M.A., Madden J.F., Fisher S.R., Scher R.L., et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head Neck 30 (2008) 262-266
-
(2008)
Head Neck
, vol.30
, pp. 262-266
-
-
Koontz, B.F.1
Miles, E.F.2
Rubio, M.A.3
Madden, J.F.4
Fisher, S.R.5
Scher, R.L.6
-
64
-
-
0028234633
-
Cellular markers that distinguish the phases of hemangioma during infancy and childhood
-
Takahashi K., Mulliken J.B., Kozakewich H.P., Rogers R.A., Folkman J., and Ezekowitz R.A. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 93 (1994) 2357-2364
-
(1994)
J Clin Invest
, vol.93
, pp. 2357-2364
-
-
Takahashi, K.1
Mulliken, J.B.2
Kozakewich, H.P.3
Rogers, R.A.4
Folkman, J.5
Ezekowitz, R.A.6
-
65
-
-
0033089048
-
Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta
-
Bielenberg D.R., Bucana C.D., Sanchez R., Mulliken J.B., Folkman J., and Fidler I.J. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta. Int J Oncol 14 (1999) 401-408
-
(1999)
Int J Oncol
, vol.14
, pp. 401-408
-
-
Bielenberg, D.R.1
Bucana, C.D.2
Sanchez, R.3
Mulliken, J.B.4
Folkman, J.5
Fidler, I.J.6
-
66
-
-
0035180453
-
Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells
-
Yu Y., Varughese J., Brown L.F., Mulliken J.B., and Bischoff J. Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am J Pathol 159 (2001) 2271-2280
-
(2001)
Am J Pathol
, vol.159
, pp. 2271-2280
-
-
Yu, Y.1
Varughese, J.2
Brown, L.F.3
Mulliken, J.B.4
Bischoff, J.5
-
67
-
-
17844407683
-
The HIF-2alpha/VEGF pathway activation in cutaneous capillary haemangiomas
-
Giatromanolaki A., Arvanitidou V., Hatzimichael A., Simopoulos C., and Sivridis E. The HIF-2alpha/VEGF pathway activation in cutaneous capillary haemangiomas. Pathology 37 (2005) 149-151
-
(2005)
Pathology
, vol.37
, pp. 149-151
-
-
Giatromanolaki, A.1
Arvanitidou, V.2
Hatzimichael, A.3
Simopoulos, C.4
Sivridis, E.5
-
68
-
-
0037188545
-
Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis
-
Ritter M.R., Dorrell M.I., Edmonds J., Friedlander S.F., and Friedlander M. Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci U S A 99 (2002) 7455-7460
-
(2002)
Proc Natl Acad Sci U S A
, vol.99
, pp. 7455-7460
-
-
Ritter, M.R.1
Dorrell, M.I.2
Edmonds, J.3
Friedlander, S.F.4
Friedlander, M.5
-
69
-
-
0028939303
-
Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases
-
Taraboletti G., Garofalo A., Belotti D., Drudis T., Borsotti P., Scanziani E., et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 87 (1995) 293-298
-
(1995)
J Natl Cancer Inst
, vol.87
, pp. 293-298
-
-
Taraboletti, G.1
Garofalo, A.2
Belotti, D.3
Drudis, T.4
Borsotti, P.5
Scanziani, E.6
-
70
-
-
0035863487
-
Inhibition of matrix metalloproteinases by over-expression of tissue inhibitor of metalloproteinase-2 inhibits the growth of experimental hemangiomas
-
Vergani V., Garofalo A., Bani M.R., Borsotti P., Parker M.P., Drudis T., et al. Inhibition of matrix metalloproteinases by over-expression of tissue inhibitor of metalloproteinase-2 inhibits the growth of experimental hemangiomas. Int J Cancer 91 (2001) 241-247
-
(2001)
Int J Cancer
, vol.91
, pp. 241-247
-
-
Vergani, V.1
Garofalo, A.2
Bani, M.R.3
Borsotti, P.4
Parker, M.P.5
Drudis, T.6
-
71
-
-
0029915612
-
Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo
-
Ramakrishnan S., Olson T.A., Bautch V.L., and Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 56 (1996) 1324-1330
-
(1996)
Cancer Res
, vol.56
, pp. 1324-1330
-
-
Ramakrishnan, S.1
Olson, T.A.2
Bautch, V.L.3
Mohanraj, D.4
-
72
-
-
0033563118
-
A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470
-
Liekens S., Verbeken E., Vandeputte M., De Clercq E., and Neyts J. A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470. Cancer Res 59 (1999) 2376-2383
-
(1999)
Cancer Res
, vol.59
, pp. 2376-2383
-
-
Liekens, S.1
Verbeken, E.2
Vandeputte, M.3
De Clercq, E.4
Neyts, J.5
-
74
-
-
4644310913
-
Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream
-
Welsh O., Olazaran Z., Gomez M., Salas J., and Berman B. Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream. J Am Acad Dermatol 51 (2004) 639-642
-
(2004)
J Am Acad Dermatol
, vol.51
, pp. 639-642
-
-
Welsh, O.1
Olazaran, Z.2
Gomez, M.3
Salas, J.4
Berman, B.5
-
75
-
-
19644378620
-
Proliferating hemangioma of infancy: successful treatment with topical 5% imiquimod cream
-
Hazen P.G., Carney J.F., Engstrom C.W., Turgeon K.L., Reep M.D., and Tanphaichitr A. Proliferating hemangioma of infancy: successful treatment with topical 5% imiquimod cream. Pediatr Dermatol 22 (2005) 254-256
-
(2005)
Pediatr Dermatol
, vol.22
, pp. 254-256
-
-
Hazen, P.G.1
Carney, J.F.2
Engstrom, C.W.3
Turgeon, K.L.4
Reep, M.D.5
Tanphaichitr, A.6
-
76
-
-
33845878022
-
Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study
-
Ho N.T., Lansang P., and Pope E. Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study. J Am Acad Dermatol 56 (2007) 63-68
-
(2007)
J Am Acad Dermatol
, vol.56
, pp. 63-68
-
-
Ho, N.T.1
Lansang, P.2
Pope, E.3
-
77
-
-
65649129285
-
A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma
-
McCuaig C.C., Dubois J., Powell J., Belleville C., David M., Rousseau E., et al. A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatr Dermatol 26 (2009) 203-212
-
(2009)
Pediatr Dermatol
, vol.26
, pp. 203-212
-
-
McCuaig, C.C.1
Dubois, J.2
Powell, J.3
Belleville, C.4
David, M.5
Rousseau, E.6
-
78
-
-
58149330199
-
Efficacy of topical application of eosin for ulcerated hemangiomas
-
Arbiser J.L. Efficacy of topical application of eosin for ulcerated hemangiomas. J Am Acad Dermatol 60 (2009) 350-351
-
(2009)
J Am Acad Dermatol
, vol.60
, pp. 350-351
-
-
Arbiser, J.L.1
-
79
-
-
45149115634
-
Propranolol for severe hemangiomas of infancy
-
Leaute-Labreze C., Dumas de la Roque E., Hubiche T., Boralevi F., Thambo J.B., and Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 358 (2008) 2649-2651
-
(2008)
N Engl J Med
, vol.358
, pp. 2649-2651
-
-
Leaute-Labreze, C.1
Dumas de la Roque, E.2
Hubiche, T.3
Boralevi, F.4
Thambo, J.B.5
Taieb, A.6
-
80
-
-
0030948107
-
Epithelioid hemangioendothelioma of skin and soft tissues: clinicopathologic and immunohistochemical study of 30 cases
-
Mentzel T., Beham A., Calonje E., Katenkamp D., and Fletcher C.D. Epithelioid hemangioendothelioma of skin and soft tissues: clinicopathologic and immunohistochemical study of 30 cases. Am J Surg Pathol 21 (1997) 363-374
-
(1997)
Am J Surg Pathol
, vol.21
, pp. 363-374
-
-
Mentzel, T.1
Beham, A.2
Calonje, E.3
Katenkamp, D.4
Fletcher, C.D.5
-
81
-
-
0030692665
-
Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo
-
Lannutti B.J., Gately S.T., Quevedo M.E., Soff G.A., and Paller A.S. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res 57 (1997) 5277-5280
-
(1997)
Cancer Res
, vol.57
, pp. 5277-5280
-
-
Lannutti, B.J.1
Gately, S.T.2
Quevedo, M.E.3
Soff, G.A.4
Paller, A.S.5
-
82
-
-
10744223783
-
Topically applied imiquimod inhibits vascular tumor growth in vivo
-
Sidbury R., Neuschler N., Neuschler E., Sun P., Wang X.Q., Miller R., et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol 121 (2003) 1205-1209
-
(2003)
J Invest Dermatol
, vol.121
, pp. 1205-1209
-
-
Sidbury, R.1
Neuschler, N.2
Neuschler, E.3
Sun, P.4
Wang, X.Q.5
Miller, R.6
-
83
-
-
43049117177
-
Pulmonary epithelioid haemangioendothelioma and bevacizumab
-
Belmont L., Zemoura L., and Couderc L.J. Pulmonary epithelioid haemangioendothelioma and bevacizumab. J Thorac Oncol 3 (2008) 557-558
-
(2008)
J Thorac Oncol
, vol.3
, pp. 557-558
-
-
Belmont, L.1
Zemoura, L.2
Couderc, L.J.3
-
84
-
-
13844315459
-
Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma
-
Mascarenhas R.C., Sanghvi A.N., Friedlander L., Geyer S.J., Beasley H.S., and Van Thiel D.H. Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma. Oncology 67 (2004) 471-475
-
(2004)
Oncology
, vol.67
, pp. 471-475
-
-
Mascarenhas, R.C.1
Sanghvi, A.N.2
Friedlander, L.3
Geyer, S.J.4
Beasley, H.S.5
Van Thiel, D.H.6
-
85
-
-
34247373748
-
AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo
-
Perry B., Banyard J., McLaughlin E.R., Watnick R., Sohn A., Brindley D.N., et al. AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo. Arch Dermatol 143 (2007) 504-506
-
(2007)
Arch Dermatol
, vol.143
, pp. 504-506
-
-
Perry, B.1
Banyard, J.2
McLaughlin, E.R.3
Watnick, R.4
Sohn, A.5
Brindley, D.N.6
-
86
-
-
33644605419
-
Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies
-
Marler J.J., Fishman S.J., Kilroy S.M., Fang J., Upton J., Mulliken J.B., et al. Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics 116 (2005) 38-45
-
(2005)
Pediatrics
, vol.116
, pp. 38-45
-
-
Marler, J.J.1
Fishman, S.J.2
Kilroy, S.M.3
Fang, J.4
Upton, J.5
Mulliken, J.B.6
-
87
-
-
0030460775
-
Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2
-
Vikkula M., Boon L.M., Carraway III K.L., Calvert J.T., Diamonti A.J., Goumnerov B., et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 87 (1996) 1181-1190
-
(1996)
Cell
, vol.87
, pp. 1181-1190
-
-
Vikkula, M.1
Boon, L.M.2
Carraway III, K.L.3
Calvert, J.T.4
Diamonti, A.J.5
Goumnerov, B.6
-
88
-
-
38149000984
-
Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo
-
Shirazi F., Cohen C., Fried L., and Arbiser J.L. Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo. Lymphat Res Biol 5 (2007) 233-236
-
(2007)
Lymphat Res Biol
, vol.5
, pp. 233-236
-
-
Shirazi, F.1
Cohen, C.2
Fried, L.3
Arbiser, J.L.4
-
89
-
-
38949157092
-
Can the wound healing response of human skin be modulated after laser treatment and the effects of exposure extended? Implications on the combined use of the pulsed dye laser and a topical angiogenesis inhibitor for treatment of port wine stain birthmarks
-
Phung T.L., Oble D.A., Jia W., Benjamin L.E., Mihm Jr. M.C., and Nelson J.S. Can the wound healing response of human skin be modulated after laser treatment and the effects of exposure extended? Implications on the combined use of the pulsed dye laser and a topical angiogenesis inhibitor for treatment of port wine stain birthmarks. Lasers Surg Med 40 (2008) 1-5
-
(2008)
Lasers Surg Med
, vol.40
, pp. 1-5
-
-
Phung, T.L.1
Oble, D.A.2
Jia, W.3
Benjamin, L.E.4
Mihm Jr., M.C.5
Nelson, J.S.6
-
90
-
-
34848879004
-
Sustained expression of Hif-1alpha in the diabetic environment promotes angiogenesis and cutaneous wound repair
-
Mace K.A., Yu D.H., Paydar K.Z., Boudreau N., and Young D.M. Sustained expression of Hif-1alpha in the diabetic environment promotes angiogenesis and cutaneous wound repair. Wound Repair Regen 15 (2007) 636-645
-
(2007)
Wound Repair Regen
, vol.15
, pp. 636-645
-
-
Mace, K.A.1
Yu, D.H.2
Paydar, K.Z.3
Boudreau, N.4
Young, D.M.5
-
91
-
-
33644693768
-
Description and analysis of treatments for port-wine stain birthmarks
-
Kelly K.M., Choi B., McFarlane S., Motosue A., Jung B., Khan M.H., et al. Description and analysis of treatments for port-wine stain birthmarks. Arch Facial Plast Surg 7 (2005) 287-294
-
(2005)
Arch Facial Plast Surg
, vol.7
, pp. 287-294
-
-
Kelly, K.M.1
Choi, B.2
McFarlane, S.3
Motosue, A.4
Jung, B.5
Khan, M.H.6
-
92
-
-
71549153877
-
Combined therapy for enhanced microvascular destruction in port wine stains: Pulsed dye laser therapy and imiquimod
-
Presented at:, Washington, DC
-
Tremain AM, Ortiz A, Armstrong J, Huang Y-C, Elkeeb L, Choi B, Kelly KM. Combined therapy for enhanced microvascular destruction in port wine stains: pulsed dye laser therapy and imiquimod. Presented at: the Annual meeting for the American Society for Laser Medicine and Surgery; 2009; Washington, DC
-
(2009)
the Annual meeting for the American Society for Laser Medicine and Surgery
-
-
Tremain, A.M.1
Ortiz, A.2
Armstrong, J.3
Huang, Y.-C.4
Elkeeb, L.5
Choi, B.6
Kelly, K.M.7
-
93
-
-
55449131051
-
Pilot study examining the combined use of pulsed dye laser and topical imiquimod versus laser alone for treatment of port wine stain birthmarks
-
Chang C.J., Hsiao Y.C., Mihm Jr. M.C., and Nelson J.S. Pilot study examining the combined use of pulsed dye laser and topical imiquimod versus laser alone for treatment of port wine stain birthmarks. Lasers Surg Med 40 (2008) 605-610
-
(2008)
Lasers Surg Med
, vol.40
, pp. 605-610
-
-
Chang, C.J.1
Hsiao, Y.C.2
Mihm Jr., M.C.3
Nelson, J.S.4
-
94
-
-
0016730483
-
Tumor angiogenic factor and human skin tumors
-
Wolf Jr. J.E., and Hubler Jr. W.R. Tumor angiogenic factor and human skin tumors. Arch Dermatol 111 (1975) 321-327
-
(1975)
Arch Dermatol
, vol.111
, pp. 321-327
-
-
Wolf Jr., J.E.1
Hubler Jr., W.R.2
-
95
-
-
0030096699
-
Pyogenic granuloma stimulates angiogenesis in the chick embryo chorioallantoic membrane
-
Ribatti D., Vacca A., Schiraldi G., Sorino S., Caprio F., Mazzotta F., et al. Pyogenic granuloma stimulates angiogenesis in the chick embryo chorioallantoic membrane. Int J Microcirc Clin Exp 16 (1996) 82-88
-
(1996)
Int J Microcirc Clin Exp
, vol.16
, pp. 82-88
-
-
Ribatti, D.1
Vacca, A.2
Schiraldi, G.3
Sorino, S.4
Caprio, F.5
Mazzotta, F.6
-
96
-
-
0034198659
-
Expression of Tie-2, angiopoietin-1, angiopoietin-2, ephrinB2 and EphB4 in pyogenic granuloma of human gingiva implicates their roles in inflammatory angiogenesis
-
Yuan K., Jin Y.T., and Lin M.T. Expression of Tie-2, angiopoietin-1, angiopoietin-2, ephrinB2 and EphB4 in pyogenic granuloma of human gingiva implicates their roles in inflammatory angiogenesis. J Periodontal Res 35 (2000) 165-171
-
(2000)
J Periodontal Res
, vol.35
, pp. 165-171
-
-
Yuan, K.1
Jin, Y.T.2
Lin, M.T.3
-
97
-
-
0034180790
-
The detection and comparison of angiogenesis-associated factors in pyogenic granuloma by immunohistochemistry
-
Yuan K., Jin Y.T., and Lin M.T. The detection and comparison of angiogenesis-associated factors in pyogenic granuloma by immunohistochemistry. J Periodontol 71 (2000) 701-709
-
(2000)
J Periodontol
, vol.71
, pp. 701-709
-
-
Yuan, K.1
Jin, Y.T.2
Lin, M.T.3
-
98
-
-
0026492897
-
Distinct localization of collagenase and tissue inhibitor of metalloproteinases expression in wound healing associated with ulcerative pyogenic granuloma
-
Saarialho-Kere U.K., Chang E.S., Welgus H.G., and Parks W.C. Distinct localization of collagenase and tissue inhibitor of metalloproteinases expression in wound healing associated with ulcerative pyogenic granuloma. J Clin Invest 90 (1992) 1952-1957
-
(1992)
J Clin Invest
, vol.90
, pp. 1952-1957
-
-
Saarialho-Kere, U.K.1
Chang, E.S.2
Welgus, H.G.3
Parks, W.C.4
-
99
-
-
0031748546
-
Inducible nitric oxide synthase is expressed in granuloma pyogenicum
-
Shimizu K., Naito S., Urata Y., Sekine I., Kondo T., and Katayama I. Inducible nitric oxide synthase is expressed in granuloma pyogenicum. Br J Dermatol 138 (1998) 769-773
-
(1998)
Br J Dermatol
, vol.138
, pp. 769-773
-
-
Shimizu, K.1
Naito, S.2
Urata, Y.3
Sekine, I.4
Kondo, T.5
Katayama, I.6
-
102
-
-
35448933306
-
Pyogenic granuloma in children: treatment with topical imiquimod
-
Fallah H., Fischer G., and Zagarella S. Pyogenic granuloma in children: treatment with topical imiquimod. Australas J Dermatol 48 (2007) 217-220
-
(2007)
Australas J Dermatol
, vol.48
, pp. 217-220
-
-
Fallah, H.1
Fischer, G.2
Zagarella, S.3
-
103
-
-
45149087717
-
Pyogenic granuloma: complete remission under occlusive imiquimod 5% cream
-
Georgiou S., Monastirli A., Pasmatzi E., and Tsambaos D. Pyogenic granuloma: complete remission under occlusive imiquimod 5% cream. Clin Exp Dermatol 33 (2008) 454-456
-
(2008)
Clin Exp Dermatol
, vol.33
, pp. 454-456
-
-
Georgiou, S.1
Monastirli, A.2
Pasmatzi, E.3
Tsambaos, D.4
-
104
-
-
33646561215
-
Successful treatment of a therapy-resistant pyogenic granuloma with topical imiquimod 5% cream
-
Goldenberg G., Krowchuk D.P., and Jorizzo J.L. Successful treatment of a therapy-resistant pyogenic granuloma with topical imiquimod 5% cream. J Dermatolog Treat 17 (2006) 121-123
-
(2006)
J Dermatolog Treat
, vol.17
, pp. 121-123
-
-
Goldenberg, G.1
Krowchuk, D.P.2
Jorizzo, J.L.3
-
105
-
-
0036713778
-
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
-
Inoki K., Li Y., Zhu T., Wu J., and Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4 (2002) 648-657
-
(2002)
Nat Cell Biol
, vol.4
, pp. 648-657
-
-
Inoki, K.1
Li, Y.2
Zhu, T.3
Wu, J.4
Guan, K.L.5
-
106
-
-
0036714127
-
Akt regulates growth by directly phosphorylating Tsc2
-
Potter C.J., Pedraza L.G., and Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 4 (2002) 658-665
-
(2002)
Nat Cell Biol
, vol.4
, pp. 658-665
-
-
Potter, C.J.1
Pedraza, L.G.2
Xu, T.3
-
107
-
-
0036712905
-
Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling
-
Gao X., Zhang Y., Arrazola P., Hino O., Kobayashi T., Yeung R.S., et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 4 (2002) 699-704
-
(2002)
Nat Cell Biol
, vol.4
, pp. 699-704
-
-
Gao, X.1
Zhang, Y.2
Arrazola, P.3
Hino, O.4
Kobayashi, T.5
Yeung, R.S.6
-
108
-
-
34447272449
-
Tuberous sclerosis complex: advances in diagnosis, genetics, and management
-
Schwartz R.A., Fernandez G., Kotulska K., and Jozwiak S. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 57 (2007) 189-202
-
(2007)
J Am Acad Dermatol
, vol.57
, pp. 189-202
-
-
Schwartz, R.A.1
Fernandez, G.2
Kotulska, K.3
Jozwiak, S.4
-
109
-
-
0041920901
-
TSC2 regulates VEGF through mTOR-dependent and -independent pathways
-
Brugarolas J.B., Vazquez F., Reddy A., Sellers W.R., and Kaelin Jr. W.G. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4 (2003) 147-158
-
(2003)
Cancer Cell
, vol.4
, pp. 147-158
-
-
Brugarolas, J.B.1
Vazquez, F.2
Reddy, A.3
Sellers, W.R.4
Kaelin Jr., W.G.5
-
110
-
-
0141705466
-
Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin
-
El-Hashemite N., Walker V., Zhang H., and Kwiatkowski D.J. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res 63 (2003) 5173-5177
-
(2003)
Cancer Res
, vol.63
, pp. 5173-5177
-
-
El-Hashemite, N.1
Walker, V.2
Zhang, H.3
Kwiatkowski, D.J.4
-
111
-
-
0037108682
-
Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors
-
Kenerson H.L., Aicher L.D., True L.D., and Yeung R.S. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 62 (2002) 5645-5650
-
(2002)
Cancer Res
, vol.62
, pp. 5645-5650
-
-
Kenerson, H.L.1
Aicher, L.D.2
True, L.D.3
Yeung, R.S.4
-
112
-
-
41449112167
-
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
-
Rauktys A., Lee N., Lee L., and Dabora S.L. Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model. BMC Dermatol 8 (2008) 1
-
(2008)
BMC Dermatol
, vol.8
, pp. 1
-
-
Rauktys, A.1
Lee, N.2
Lee, L.3
Dabora, S.L.4
-
113
-
-
47549093135
-
The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis
-
Hofbauer G.F., Marcollo-Pini A., Corsenca A., Kistler A.D., French L.E., Wuthrich R.P., et al. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol 159 (2008) 473-475
-
(2008)
Br J Dermatol
, vol.159
, pp. 473-475
-
-
Hofbauer, G.F.1
Marcollo-Pini, A.2
Corsenca, A.3
Kistler, A.D.4
French, L.E.5
Wuthrich, R.P.6
-
114
-
-
0027980960
-
Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis
-
Detmar M., Brown L.F., Claffey K.P., Yeo K.T., Kocher O., Jackman R.W., et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180 (1994) 1141-1146
-
(1994)
J Exp Med
, vol.180
, pp. 1141-1146
-
-
Detmar, M.1
Brown, L.F.2
Claffey, K.P.3
Yeo, K.T.4
Kocher, O.5
Jackman, R.W.6
-
115
-
-
0033387917
-
Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis
-
Bhushan M., McLaughlin B., Weiss J.B., and Griffiths C.E. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 141 (1999) 1054-1060
-
(1999)
Br J Dermatol
, vol.141
, pp. 1054-1060
-
-
Bhushan, M.1
McLaughlin, B.2
Weiss, J.B.3
Griffiths, C.E.4
-
116
-
-
0038644624
-
Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis
-
Xia Y.P., Li B., Hylton D., Detmar M., Yancopoulos G.D., and Rudge J.S. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102 (2003) 161-168
-
(2003)
Blood
, vol.102
, pp. 161-168
-
-
Xia, Y.P.1
Li, B.2
Hylton, D.3
Detmar, M.4
Yancopoulos, G.D.5
Rudge, J.S.6
-
117
-
-
42349097330
-
Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF
-
Man X.Y., Yang X.H., Cai S.Q., Bu Z.Y., and Zheng M. Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF. J Cell Mol Med 12 (2008) 649-660
-
(2008)
J Cell Mol Med
, vol.12
, pp. 649-660
-
-
Man, X.Y.1
Yang, X.H.2
Cai, S.Q.3
Bu, Z.Y.4
Zheng, M.5
-
118
-
-
20444497652
-
Psoriasis-recent advances in understanding its pathogenesis and treatment
-
Krueger G., and Ellis C.N. Psoriasis-recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 53 (2005) S94-100
-
(2005)
J Am Acad Dermatol
, vol.53
-
-
Krueger, G.1
Ellis, C.N.2
-
119
-
-
0028223727
-
Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis
-
Nickoloff B.J., Mitra R.S., Varani J., Dixit V.M., and Polverini P.J. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 144 (1994) 820-828
-
(1994)
Am J Pathol
, vol.144
, pp. 820-828
-
-
Nickoloff, B.J.1
Mitra, R.S.2
Varani, J.3
Dixit, V.M.4
Polverini, P.J.5
-
120
-
-
0035012596
-
Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis
-
Kuroda K., Sapadin A., Shoji T., Fleischmajer R., and Lebwohl M. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol 116 (2001) 713-720
-
(2001)
J Invest Dermatol
, vol.116
, pp. 713-720
-
-
Kuroda, K.1
Sapadin, A.2
Shoji, T.3
Fleischmajer, R.4
Lebwohl, M.5
-
121
-
-
0030480322
-
Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
-
Suri C., Jones P.F., Patan S., Bartunkova S., Maisonpierre P.C., Davis S., et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87 (1996) 1171-1180
-
(1996)
Cell
, vol.87
, pp. 1171-1180
-
-
Suri, C.1
Jones, P.F.2
Patan, S.3
Bartunkova, S.4
Maisonpierre, P.C.5
Davis, S.6
-
122
-
-
0034786155
-
Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial
-
Reitamo S., Spuls P., Sassolas B., Lahfa M., Claudy A., and Griffiths C.E. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 145 (2001) 438-445
-
(2001)
Br J Dermatol
, vol.145
, pp. 438-445
-
-
Reitamo, S.1
Spuls, P.2
Sassolas, B.3
Lahfa, M.4
Claudy, A.5
Griffiths, C.E.6
-
123
-
-
17644374126
-
Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial
-
Ormerod A.D., Shah S.A., Copeland P., Omar G., and Winfield A. Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. Br J Dermatol 152 (2005) 758-764
-
(2005)
Br J Dermatol
, vol.152
, pp. 758-764
-
-
Ormerod, A.D.1
Shah, S.A.2
Copeland, P.3
Omar, G.4
Winfield, A.5
-
124
-
-
33745305095
-
Anti-angiogenic drugs: from bench to clinical trials
-
Quesada A.R., Munoz-Chapuli R., and Medina M.A. Anti-angiogenic drugs: from bench to clinical trials. Med Res Rev 26 (2006) 483-530
-
(2006)
Med Res Rev
, vol.26
, pp. 483-530
-
-
Quesada, A.R.1
Munoz-Chapuli, R.2
Medina, M.A.3
-
125
-
-
33847020465
-
SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis
-
Keshtgarpour M., and Dudek A.Z. SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis. Transl Res 149 (2007) 103-106
-
(2007)
Transl Res
, vol.149
, pp. 103-106
-
-
Keshtgarpour, M.1
Dudek, A.Z.2
-
126
-
-
25444468047
-
Dobesilate in the treatment of plaque psoriasis
-
Cuevas P., and Arrazola J.M. Dobesilate in the treatment of plaque psoriasis. Eur J Med Res 10 (2005) 373-376
-
(2005)
Eur J Med Res
, vol.10
, pp. 373-376
-
-
Cuevas, P.1
Arrazola, J.M.2
-
127
-
-
29244468263
-
Videocapillaroscopic alterations in erythematotelangiectatic rosacea
-
Rosina P., Zamperetti M.R., Giovannini A., Chieregato C., and Girolomoni G. Videocapillaroscopic alterations in erythematotelangiectatic rosacea. J Am Acad Dermatol 54 (2006) 100-104
-
(2006)
J Am Acad Dermatol
, vol.54
, pp. 100-104
-
-
Rosina, P.1
Zamperetti, M.R.2
Giovannini, A.3
Chieregato, C.4
Girolomoni, G.5
-
128
-
-
34648830374
-
Lymphangiogenesis and angiogenesis in non-phymatous rosacea
-
Gomaa A.H., Yaar M., Eyada M.M., and Bhawan J. Lymphangiogenesis and angiogenesis in non-phymatous rosacea. J Cutan Pathol 34 (2007) 748-753
-
(2007)
J Cutan Pathol
, vol.34
, pp. 748-753
-
-
Gomaa, A.H.1
Yaar, M.2
Eyada, M.M.3
Bhawan, J.4
-
129
-
-
33846804401
-
Expression of vascular endothelial growth factor and its receptors in rosacea
-
Smith J.R., Lanier V.B., Braziel R.M., Falkenhagen K.M., White C., and Rosenbaum J.T. Expression of vascular endothelial growth factor and its receptors in rosacea. Br J Ophthalmol 91 (2007) 226-229
-
(2007)
Br J Ophthalmol
, vol.91
, pp. 226-229
-
-
Smith, J.R.1
Lanier, V.B.2
Braziel, R.M.3
Falkenhagen, K.M.4
White, C.5
Rosenbaum, J.T.6
-
130
-
-
48349087831
-
Antimicrobial peptides and the skin immune defense system
-
Schauber J., and Gallo R.L. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol 122 (2008) 261-266
-
(2008)
J Allergy Clin Immunol
, vol.122
, pp. 261-266
-
-
Schauber, J.1
Gallo, R.L.2
-
131
-
-
0345074069
-
Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide
-
Di Nardo A., Vitiello A., and Gallo R.L. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol 170 (2003) 2274-2278
-
(2003)
J Immunol
, vol.170
, pp. 2274-2278
-
-
Di Nardo, A.1
Vitiello, A.2
Gallo, R.L.3
-
133
-
-
0038142308
-
An angiogenic role for the human peptide antibiotic LL-37/hCAP-18
-
Koczulla R., von Degenfeld G., Kupatt C., Krotz F., Zahler S., Gloe T., et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 111 (2003) 1665-1672
-
(2003)
J Clin Invest
, vol.111
, pp. 1665-1672
-
-
Koczulla, R.1
von Degenfeld, G.2
Kupatt, C.3
Krotz, F.4
Zahler, S.5
Gloe, T.6
-
134
-
-
84920106848
-
-
Deindl E., and Kupatt C. (Eds), Springer-Verlag, New York
-
In: Deindl E., and Kupatt C. (Eds). Therapeutic neovascularization: quo vadis? (2007), Springer-Verlag, New York
-
(2007)
Therapeutic neovascularization: quo vadis?
-
-
-
135
-
-
42449090687
-
LL-37 regulates the overexpression of vascular endothelial growth factor (VEGF) and c-IAP-2 in human keratinocytes
-
Rodriguez-Martinez S., Cancino-Diaz J.C., Vargas-Zuniga L.M., and Cancino-Diaz M.E. LL-37 regulates the overexpression of vascular endothelial growth factor (VEGF) and c-IAP-2 in human keratinocytes. Int J Dermatol 47 (2008) 457-462
-
(2008)
Int J Dermatol
, vol.47
, pp. 457-462
-
-
Rodriguez-Martinez, S.1
Cancino-Diaz, J.C.2
Vargas-Zuniga, L.M.3
Cancino-Diaz, M.E.4
-
136
-
-
34547660319
-
Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea
-
Yamasaki K., Di Nardo A., Bardan A., Murakami M., Ohtake T., Coda A., et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 13 (2007) 975-980
-
(2007)
Nat Med
, vol.13
, pp. 975-980
-
-
Yamasaki, K.1
Di Nardo, A.2
Bardan, A.3
Murakami, M.4
Ohtake, T.5
Coda, A.6
-
137
-
-
27744572068
-
Therapeutic response of rosacea to dobesilate
-
Cuevas P., and Arrazola J.M. Therapeutic response of rosacea to dobesilate. Eur J Med Res 10 (2005) 454-456
-
(2005)
Eur J Med Res
, vol.10
, pp. 454-456
-
-
Cuevas, P.1
Arrazola, J.M.2
-
138
-
-
0034783801
-
Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis
-
Chan L.S., Robinson N., and Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol 117 (2001) 977-983
-
(2001)
J Invest Dermatol
, vol.117
, pp. 977-983
-
-
Chan, L.S.1
Robinson, N.2
Xu, L.3
-
139
-
-
25444517290
-
The disease progression in the keratin 14 IL-4-transgenic mouse model of atopic dermatitis parallels the up-regulation of B cell activation molecules, proliferation and surface and serum IgE
-
Chen L., Lin S.X., Overbergh L., Mathieu C., and Chan L.S. The disease progression in the keratin 14 IL-4-transgenic mouse model of atopic dermatitis parallels the up-regulation of B cell activation molecules, proliferation and surface and serum IgE. Clin Exp Immunol 142 (2005) 21-30
-
(2005)
Clin Exp Immunol
, vol.142
, pp. 21-30
-
-
Chen, L.1
Lin, S.X.2
Overbergh, L.3
Mathieu, C.4
Chan, L.S.5
-
140
-
-
9644302965
-
Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model
-
Chen L., Martinez O., Overbergh L., Mathieu C., Prabhakar B.S., and Chan L.S. Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model. Clin Exp Immunol 138 (2004) 375-387
-
(2004)
Clin Exp Immunol
, vol.138
, pp. 375-387
-
-
Chen, L.1
Martinez, O.2
Overbergh, L.3
Mathieu, C.4
Prabhakar, B.S.5
Chan, L.S.6
-
141
-
-
13544256255
-
Correlation of disease evolution with progressive inflammatory cell activation and migration in the IL-4 transgenic mouse model of atopic dermatitis
-
Chen L., Martinez O., Venkataramani P., Lin S.X., Prabhakar B.S., and Chan L.S. Correlation of disease evolution with progressive inflammatory cell activation and migration in the IL-4 transgenic mouse model of atopic dermatitis. Clin Exp Immunol 139 (2005) 189-201
-
(2005)
Clin Exp Immunol
, vol.139
, pp. 189-201
-
-
Chen, L.1
Martinez, O.2
Venkataramani, P.3
Lin, S.X.4
Prabhakar, B.S.5
Chan, L.S.6
-
142
-
-
25144450231
-
Angiogenesis: the major abnormality of the keratin-14 IL-4 transgenic mouse model of atopic dermatitis
-
Agha-Majzoub R., Becker R.P., Schraufnagel D.E., and Chan L.S. Angiogenesis: the major abnormality of the keratin-14 IL-4 transgenic mouse model of atopic dermatitis. Microcirculation 12 (2005) 455-476
-
(2005)
Microcirculation
, vol.12
, pp. 455-476
-
-
Agha-Majzoub, R.1
Becker, R.P.2
Schraufnagel, D.E.3
Chan, L.S.4
-
143
-
-
38049161744
-
The progression of inflammation parallels the dermal angiogenesis in a keratin 14 IL-4-transgenic model of atopic dermatitis
-
Chen L., Marble D.J., Agha R., Peterson J.D., Becker R.P., Jin T., et al. The progression of inflammation parallels the dermal angiogenesis in a keratin 14 IL-4-transgenic model of atopic dermatitis. Microcirculation 15 (2008) 49-64
-
(2008)
Microcirculation
, vol.15
, pp. 49-64
-
-
Chen, L.1
Marble, D.J.2
Agha, R.3
Peterson, J.D.4
Becker, R.P.5
Jin, T.6
-
144
-
-
33344476172
-
Increased production of vascular endothelial growth factor in the lesions of atopic dermatitis
-
Zhang Y., Matsuo H., and Morita E. Increased production of vascular endothelial growth factor in the lesions of atopic dermatitis. Arch Dermatol Res 297 (2006) 425-429
-
(2006)
Arch Dermatol Res
, vol.297
, pp. 425-429
-
-
Zhang, Y.1
Matsuo, H.2
Morita, E.3
-
145
-
-
12444299991
-
Mast cells and vasculature in atopic dermatitis-potential stimulus of neoangiogenesis
-
Groneberg D.A., Bester C., Grutzkau A., Serowka F., Fischer A., Henz B.M., et al. Mast cells and vasculature in atopic dermatitis-potential stimulus of neoangiogenesis. Allergy 60 (2005) 90-97
-
(2005)
Allergy
, vol.60
, pp. 90-97
-
-
Groneberg, D.A.1
Bester, C.2
Grutzkau, A.3
Serowka, F.4
Fischer, A.5
Henz, B.M.6
-
146
-
-
0018581426
-
Mast cell population density, blood vessel density and histamine content in normal human skin
-
Eady R.A., Cowen T., Marshall T.F., Plummer V., and Greaves M.W. Mast cell population density, blood vessel density and histamine content in normal human skin. Br J Dermatol 100 (1979) 623-633
-
(1979)
Br J Dermatol
, vol.100
, pp. 623-633
-
-
Eady, R.A.1
Cowen, T.2
Marshall, T.F.3
Plummer, V.4
Greaves, M.W.5
-
147
-
-
2142657200
-
Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts
-
Wu Y., Zhang Q., Ann D.K., Akhondzadeh A., Duong H.S., Messadi D.V., et al. Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts. Am J Physiol Cell Physiol 286 (2004) C905-C912
-
(2004)
Am J Physiol Cell Physiol
, vol.286
-
-
Wu, Y.1
Zhang, Q.2
Ann, D.K.3
Akhondzadeh, A.4
Duong, H.S.5
Messadi, D.V.6
-
148
-
-
33846258102
-
Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion
-
Ong C.T., Khoo Y.T., Tan E.K., Mukhopadhyay A., Do D.V., Han H.C., et al. Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion. J Pathol 211 (2007) 95-108
-
(2007)
J Pathol
, vol.211
, pp. 95-108
-
-
Ong, C.T.1
Khoo, Y.T.2
Tan, E.K.3
Mukhopadhyay, A.4
Do, D.V.5
Han, H.C.6
-
149
-
-
59949086075
-
Akt1 controls insulin-driven VEGF biosynthesis from keratinocytes: implications for normal and diabetes-impaired skin repair in mice
-
Goren I., Müller E., Schiefelbein D., Gutwein P., Seitz O., Pfeilschifter J., et al. Akt1 controls insulin-driven VEGF biosynthesis from keratinocytes: implications for normal and diabetes-impaired skin repair in mice. J Invest Dermatol 129 (2009) 752-764
-
(2009)
J Invest Dermatol
, vol.129
, pp. 752-764
-
-
Goren, I.1
Müller, E.2
Schiefelbein, D.3
Gutwein, P.4
Seitz, O.5
Pfeilschifter, J.6
-
150
-
-
66849094045
-
Recombinant human platelet-derived growth factor enhances repair of cutaneous full-thickness excision by increasing the phosphorylation of extracellular signal-regulated kinase in diabetic rat
-
Cheng B., Liu H., Fu X., Sheng Z., and Sun T. Recombinant human platelet-derived growth factor enhances repair of cutaneous full-thickness excision by increasing the phosphorylation of extracellular signal-regulated kinase in diabetic rat. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 20 (2006) 1093-1098
-
(2006)
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
, vol.20
, pp. 1093-1098
-
-
Cheng, B.1
Liu, H.2
Fu, X.3
Sheng, Z.4
Sun, T.5
-
151
-
-
33745513688
-
Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers
-
Steed D.L. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers. Plast Reconstr Surg 117 7 suppl (2006) 143S-149S
-
(2006)
Plast Reconstr Surg
, vol.117
, Issue.7 SUPPL
-
-
Steed, D.L.1
|